At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 49 enrolled
Drug / intervention
Daratumumab +2 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Trial of Daratumumab for Transplant-Eligible Multiple Myeloma Patients
In Brief
A Phase 2 clinical trial evaluating Autologous Hematopoietic Stem Cell Transplantation, Daratumumab, and 1 other intervention for Plasma Cell Myeloma. Completed, enrolled 49 participants across 1 site.
Detailed Summary
This phase II trial studies how well daratumumab works in treating transplant-eligible patients with multiple myeloma. Daratumumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPlasma Cell Myeloma
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedMar 2018
Enrollment StartApr 2018
Primary CompletionMay 2022
Study CompletionMar 2025
TodayJul 2026
First PostedMar 26, 2018
Enrollment StartApr 9, 2018
Primary CompletionMay 11, 2022
Study CompletionMar 24, 2025
TodayJul 2, 2026
Enrollment to primary: 4.1 yearsPosted 8.3 years ago
Interventions
Autologous Hematopoietic Stem Cell Transplantationprocedure
Undergo ASCT
Daratumumabbiological
Given IV
Lenalidomidedrug
Given PO